PUTH is a comprehensive First Class of the Third Grade Hospital. It is the Standardized Training Base of the National Health Commission for Specialists, the Professional Base of Beijing for Standardized Residents Training in Hospital, and the Skills Assessment Center of Beijing for Standardized Residents Training in Hospital. It has 20 national key clinical sections, 70 on-the-job doctoral supervisors, 1 CAS Member, and 2 CAE Members.

As a technical service platform of PUTH for clinical trials of drugs and medical devices, the Drug Clinical Trials Institute (DCTC) of PUTH has built a One-stop Early Clinical Research Platform for innovative drugs for metabolic diseases, cardiovascular diseases and tumors, and has been responsible for the early clinical development or model guided clinical development projects of more than 40 Class 1.1 Innovative Drugs.

Leadingpharm

Leadingpharm was established in 2005, reorganized with Henan Taloph Pharmaceutical Stock in 2015 (stock code: 600222). Leadingpharm is committed to promoting the development of China's pharmaceutical industry with innovative R&D and service models, together with information technology. Based on the international perspective, Leadingpharm has formed the core competitive advantage of "internationalization, integration and industrialization". Based on its mature and complete management system of pharmaceutical R&D, rich project experience and a team of more than 1000 senior experts at home and abroad, Leadingpharm has built the CXO Whole Industry Chain Service System covering preclinical research, clinical CRO, CDMO and MAH, and achieved full coverage of innovative drugs, high-end complex preparations, cell gene therapy drugs and other fields, which can provide global customers with a truly one-stop service.
 

-END-